Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > New Paper from Dr. McFarland
View:
Post by Eoganacht on Jan 08, 2022 4:54pm

New Paper from Dr. McFarland

Dr. McFarland is having a go at photodynamic inactivation of coronaviruses with the botanical extract PhytoQuin as the photosensitizer. I don't think Theralase has the rights to this one. The full text is available here:

Photodynamic Inactivation of Human Coronaviruses

Abstract:

Photodynamic inactivation (PDI) employs a photosensitizer, light, and oxygen to create a local burst of reactive oxygen species (ROS) that can inactivate microorganisms. The botanical extract PhytoQuinTM is a powerful photosensitizer with antimicrobial properties. We previously demonstrated that photoactivated PhytoQuin also has antiviral properties against herpes simplex viruses and adenoviruses in a dose-dependent manner across a broad range of sub-cytotoxic concentrations. Here, we report that human coronaviruses (HCoVs) are also susceptible to photodynamic inactivation. Photoactivated-PhytoQuin inhibited the replication of the alphacoronavirus HCoV229E and the betacoronavirus HCoV-OC43 in cultured cells across a range of sub-cytotoxic doses.
 
This antiviral effect was light-dependent, as we observed minimal antiviral effect of PhytoQuin in the absence of photoactivation. Using RNase protection assays, we observed that PDI disrupted HCoV particle integrity allowing for the digestion of viral RNA by exogenous ribonucleases. Using lentiviruses pseudotyped with the SARS-CoV-2 Spike (S) protein, we once again observed a strong, light-dependent antiviral effect of PhytoQuin, which prevented S-mediated entry into human cells. We also observed that PhytoQuin PDI altered S protein electrophoretic mobility. The PhytoQuin constituent emodin displayed equivalent light-dependent antiviral activity to PhytoQuin in matched dose experiments, indicating that it plays a central role in PhytoQuin PDI against CoVs. Together, these findings demonstrate that HCoV lipid envelopes and proteins are damaged by PhytoQuin PDI and expands the list of susceptible viruses.
Comment by Eoganacht on Jan 08, 2022 4:57pm
Theralase definitely doesn't have the rights to this photosenstizer. It is owned by Dr. McFarland's own privately held company - Photodynamic Inc.
Comment by 99942Apophis on Jan 08, 2022 7:04pm
I would imagine out of Professional courtesy Dr. SHERRI MCFARLAND had a discussion with Theralase. Will be looking at the next Newsletter to see if anything is mentioned and it wouldn't make sense for Theralase to go forward if Dr. McFarland has initiated a move. My gut feeling would be they had a conversation and Theralase will concentrate on Cancer while she tackles the Coronavirus,  ...more  
Comment by CancerSlayer on Jan 09, 2022 3:08pm
[/quote/] I'm still encouraged by TLD-1433's ability to destroy enveloped viruses at safe/non-cytotoxic doses "without" the need for light activation.  I think this may separate us from other photosensitizing compounds, including Dr. McFarland's new compound, PhytoQuin.   As stated per Dr. Coombs of U of M:   “From this initial data, Theralase’s PDCs ...more  
Comment by Eoganacht on Jan 09, 2022 3:18pm
Personally I don't think there is any question of Dr. McFarland competing with Theralase. Any progress Theralase makes represents progress for her lifes work. Who knows where her research with her photosensitizer PhytoQuin might lead - maybe a cure for the common cold? Wherever it leads I don't think it will conflict with the commercialization of her other photosensitizer TLD1433.
Comment by 99942Apophis on Jan 09, 2022 4:05pm
Thank you for your thoughts CancerSlayer & Eoganacht I also have no worries about Theralase's abilities to fight Cancers and other pathogens. If Dr. McFarland aim is solely to bring a fix all vaccine or treatment to the world for Coronavirus it will also bring a strong light on Theralase's cancer treatment, good for everyone, if the light shines on her it will also shine on us! 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250